Coverage
-
March 06, 2015
A California federal judge declined to invalidate two Genentech Inc. patents covering biotechnology used to make drugs for cancer and autoimmune diseases, ruling Thursday that Eli Lilly and Co.'s arguments that the method was double-patented were unpersuasive.
1 other articles on this case.
View all »